Table 2. Univariate Cox regression models of disease-free-survival (DFS) in 61 CRC patients on stage I-III.
| no. event/total number | hazard ratio | 95%CI | p-value | ||
| Age (years) | continuous | 1.0 | 0.8-1.1 | 0.6965 | |
| Gender | F | 8/27 | 1 | ||
| M | 7/34 | 0.8 | 0.3-2.2 | 0.6948 | |
| Stage | I-II | 5/25 | 1 | ||
| III | 10/36 | 1.6 | 0.6-4.8 | 0.3671 | |
| Site | Right | 8/29 | 1 | ||
| Left | 6/25 | 0.9 | 0.3-2.5 | 0.7845 | |
| Rectum | 1/7 | 0.5 | 0.1-4.1 | 0.5218 | |
| Adjuvant therapy | No | 5/14 | 1.8 | 0.6-5.3 | 0.2833 |
| Yes | 10/47 | 1 | |||
| Geriatric assessment | Fit | 11/40 | 1 | ||
| Vuln/Frail | 4/21 | 0.7 | 0.2-2.2 | 0.4911 | |
| IL6 | <=5.31 | 12/54 | 1 | ||
| >best | 2/4 | 5.6 | 1.1-28.7 | 0.0368 | |
| CRP | <=5.94 | 11/49 | 1 | ||
| >best | 4/10 | 2.2 | 0.7-7.0 | 0.1682 | |
| Telomere length (T/S) | <=1.37 | 7/33 | 1 | ||
| >best | 6/16 | 1.9 | 0.6-5.6 | 0.2644 | |
| TREC/105 PBMC | <=40 | 9/37 | 1 | ||
| >best | 6/17 | 1.6 | 0.6-4.5 | 0.3726 | |
| % CD8 recent thymic emigrant cells | <=33.53 | 1/23 | 1 | ||
| (CD8+CD45RA+CD31+) | >best | 12/33 | 8.4 | 1.1-64.7 | 0.0410 |
| % CD4 recent thymic emigrant cells | <=21.42 | 10/35 | 1.8 | 0.6-5.8 | 0.3065 |
| (CD4+CD45RA+CD31+) | >best | 4/21 | 1 | ||
| % CD8 activated cells | <=6.7 | 11/53 | 1 | ||
| (CD8+CD38+HLA-DR+) | >best | 3/5 | 4.1 | 1.1-15.0 | 0.0297 |
| %CD8 senescent cells | <=43.96 | 4/25 | 1 | ||
| (CD8+CD28-CD57+) | >best | 8/17 | 3.5 | 1.0-11.6 | 0.0434 |
| %CD4 senescent cells | <=12.83 | 6/32 | 1 | ||
| (CD4+CD28-CD57+) | >best | 4/9 | 2.4 | 0.7-8.6 | 0.1680 |
| CD4/CD8 ratio | <=0.68 | 4/6 | 7.0 | 2.1-23.3 | 0.0014 |
| >best | 10/54 | 1 |